KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

NovoCure (NVCR) Operating Expenses (2016 - 2025)

NovoCure (NVCR) has disclosed Operating Expenses for 12 consecutive years, with $172.6 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses fell 9.69% to $172.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $642.3 million through Dec 2025, up 0.59% year-over-year, with the annual reading at $642.3 million for FY2025, 0.59% up from the prior year.
  • Operating Expenses hit $172.6 million in Q4 2025 for NovoCure, up from $158.5 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $191.1 million in Q4 2024 to a low of $108.4 million in Q1 2021.
  • Historically, Operating Expenses has averaged $143.6 million across 5 years, with a median of $150.5 million in 2024.
  • Biggest five-year swings in Operating Expenses: surged 39.9% in 2021 and later dropped 9.69% in 2025.
  • Year by year, Operating Expenses stood at $126.9 million in 2021, then rose by 12.29% to $142.5 million in 2022, then rose by 7.31% to $152.9 million in 2023, then rose by 24.95% to $191.1 million in 2024, then decreased by 9.69% to $172.6 million in 2025.
  • Business Quant data shows Operating Expenses for NVCR at $172.6 million in Q4 2025, $158.5 million in Q3 2025, and $156.9 million in Q2 2025.